M.E.A.C. Engineering v. Molnlycke Health Care: Wound Closure Patents Settled in 116 Days
M.E.A.C. Engineering, Ltd. filed a patent infringement action against Molnlycke Health Care AG and its US subsidiary in the Northern District of Georgia, asserting two wound closure and drainage system patents. The parties reached a settlement within 116 days — an unusually swift resolution for a multi-patent infringement dispute.
Wound closure IP dispute resolved swiftly as parties agree to settle
On 12 January 2024, M.E.A.C. Engineering, Ltd. filed a patent infringement complaint against Molnlycke Health Care AG and its US operating entity, Molnlycke Health Care US, LLC, in the Northern District of Georgia before Judge Michael L. Brown. The plaintiff asserted two granted US patents — US8506554B2 and US8858534B2 — both directed to wound closure and drainage system technology, against the defendants’ products in that category.
On 7 May 2024 — just 116 days after filing — the parties jointly moved to stay all deadlines and notified the court of a settlement in principle. Judge Brown granted the motion, administratively closing the case and directing the parties to file formal dismissal papers upon finalisation of the settlement. The public record does not disclose financial terms, licensing arrangements, or which party’s position prevailed in the negotiated outcome.
A resolution within four months is notably swift for a two-patent district court infringement action, suggesting both parties had strong commercial incentives to avoid protracted litigation. The administrative closure rather than an immediate dismissal indicates settlement documentation was still being finalised as of the court’s order. Whether the resolution involved a licence, cross-licence, or simple covenant-not-to-sue remains unknown from publicly available filings.
Filing to Case Stayed in 116 days
116 days — faster than the typical district court patent case median of 2+ years
Case settled: what the administrative closure means for both parties
Administrative closure after settlement notice — not a final dismissal
An administrative closure under these circumstances is a procedural holding measure. The court accepted the parties’ joint representation that a settlement had been reached and stayed all deadlines for 30 days to allow formal dismissal papers to be filed. The case has not been formally dismissed; it remains subject to reopening if settlement negotiations fail. Final disposition awaits a Rule 41 stipulation or consent judgment.
Settlement in principleM.E.A.C. Engineering avoids trial risk — terms undisclosed
M.E.A.C. Engineering secured an early resolution without exposing its patents to a full validity and infringement analysis at trial. Settlement at this stage — before claim construction — typically preserves patent strength and avoids narrowing rulings. Whether M.E.A.C. obtained royalties, a licence fee, or other consideration is not disclosed in the public record. The patents remain in force.
Patents intactMolnlycke avoids infringement finding but terms are sealed
Molnlycke Health Care avoided a potentially adverse infringement ruling and the associated damages exposure. Settlement before claim construction also means no court-issued claim interpretation narrows or expands the asserted patents against Molnlycke specifically. However, the absence of a merits ruling means the patents’ scope is unchanged and could be asserted against others in the wound care market.
No merits rulingEarly settlement leaves wound closure IP landscape unresolved
Because the dispute settled before any substantive court rulings, competitors in the wound closure and drainage space receive no claim construction guidance from this case. US8506554B2 and US8858534B2 remain asserted, enforceable, and uninterpreted by a court. Other manufacturers whose products overlap with these patent claims should treat this outcome as a signal that M.E.A.C. is willing to enforce its portfolio — and potentially reach commercial terms — rather than litigate to judgment.
Enforce risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | M.E.A.C. Engineering, Ltd. | Company | Medical device IP holder — holder of US8506554B2 and US8858534B2 (wound closure and drainage)Search in Eureka ↗ |
| Defendant | Molnlycke Health Care, AG | Company | Global wound care manufacturer Molnlycke Health Care AG and its US subsidiarySearch in Eureka ↗ |
| Co-Defendant | Molnlycke Health Care US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Joseph Jude Zito | Attorney | Counsel for M.E.A.C. Engineering, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Samuel S. Woodhouse , III | Attorney | Counsel for M.E.A.C. Engineering, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Dnl Zito Castellano | Law Firm | Representing M.E.A.C. Engineering, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | The Woodhouse Law Firm, LLC | Law Firm | Representing M.E.A.C. Engineering, Ltd.Search in Eureka ↗ |
| Defendant counsel | Christopher P. Damitio | Attorney | Counsel for Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant counsel | David C. Holloway | Attorney | Counsel for Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant counsel | Kasey E. Koballa | Attorney | Counsel for Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant counsel | Steven D. Moore | Attorney | Counsel for Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant law firm | Kilpatrick Townsend & Stockton LLP | Law Firm | Representing Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant law firm | Kilpatrick Townsend & Stockton LLP (ATL) | Law Firm | Representing Molnlycke Health Care, AGSearch in Eureka ↗ |
| Defendant law firm | Kilpatrick Townsend & Stockton, LLP – Raleigh | Law Firm | Representing Molnlycke Health Care, AGSearch in Eureka ↗ |
| Presiding judge | Judge Michael L. Brown | Judge | Georgia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order does not adjudicate infringement or validity — it is a procedural stay granted on joint motion following notice of settlement. The language ‘for good cause shown’ reflects the court’s acceptance of the parties’ representations without any merits analysis. The administrative closure is not a final judgment; the case remains nominally open and can be reinstated. The settlement terms, including any financial consideration or licence grant, are not part of the public record.
US8506554B2 & US8858534B2 — Wound Closure and Drainage System Patents
US8506554B2 and US8858534B2 are granted US utility patents directed to wound closure and drainage system technology. US8858534B2 (application 13/917865) appears to be a continuation of the earlier application family (11/989297, issuing as US8506554B2), suggesting a deliberate prosecution strategy to secure layered claim coverage across apparatus and method aspects of the same core invention. Both patents were asserted together, which is consistent with a portfolio enforcement approach designed to maximise claim breadth and hedge against potential invalidity of individual claims.
Wound closure and drainage systems — including negative-pressure wound therapy (NPWT) and related closure technologies — represent a high-value, actively litigated segment of the medical device IP landscape. Molnlycke Health Care is a major global competitor in advanced wound care, making it a commercially significant enforcement target. The fact that two patents were asserted simultaneously against a defendant of this scale suggests M.E.A.C. Engineering views its patent family as commercially valuable and enforceable. Other wound care manufacturers should assess their exposure to this patent family before launching or expanding products in this category.
Should your product team run an FTO against US8506554B2 and US8858534B2?
Any company developing or commercialising wound closure systems, drainage devices, or negative-pressure wound therapy products in the US market should treat these two patents as active enforcement risks. M.E.A.C. Engineering has demonstrated willingness to assert both patents simultaneously against a major global wound care brand — and to reach a settlement, suggesting the claims have credible commercial reach. Product teams preparing to launch in this space should commission a freedom-to-operate analysis before market entry.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map claim scope against US8506554B2 and US8858534B2 in minutes, identifying claim elements that may read on a proposed product design. Eureka’s AI-assisted claim charting and prior art synthesis can flag design-around opportunities or support a non-infringement position — reducing legal spend and accelerating time to market for wound care product teams.
Run a freedom-to-operate analysis on US8506554B2 to assess your product’s exposure
Run FTO in Eureka →Similar wound closure and medical device patent cases in US district courts
Explore related patent infringement actions involving wound closure, drainage systems, and medical device IP litigated in US district courts, including the Northern District of Georgia.
What this case signals for the wound care IP enforcement landscape
A 116-day settlement in a two-patent wound closure case suggests active portfolio monetisation and a commercially pragmatic defendant.
Pre-claim-construction settlement preserves patent scope for future enforcement
No claim construction order was issued, meaning US8506554B2 and US8858534B2 remain uninterpreted by any court. M.E.A.C. Engineering retains full flexibility to assert these patents against additional defendants at their broadest reasonable scope. Competitors in wound closure and drainage should not assume this settlement signals a narrow or weak patent position.
Molnlycke’s swift settlement suggests credible infringement exposure
Molnlycke retained four attorneys from Kilpatrick Townsend & Stockton — a substantial defence team — yet settled within 116 days. This pattern is consistent with defendants who assess early that litigation costs and infringement risk outweigh settlement costs, particularly where the patented technology is core to a commercial product line.
M.E.A.C. v Molnlycke — key questions answered
M.E.A.C. Engineering asserted two US patents: US8506554B2 (application 11/989297) and US8858534B2 (application 13/917865), both covering wound closure and drainage system technology. Both patents were asserted simultaneously in the infringement complaint filed on 12 January 2024 in the Northern District of Georgia.
The case was resolved through settlement. On 7 May 2024 — 116 days after filing — the parties filed a joint Motion to Stay All Deadlines and Notice of Settlement. Judge Michael L. Brown granted the stay, administratively closing the case and directing the parties to file formal dismissal papers upon finalisation of the settlement. Financial terms are not publicly disclosed.
No. An administrative closure following settlement notice does not constitute a court ruling on validity or infringement. Both patents remain in force and uninterpreted by any court. Because no claim construction order was issued, the patents retain their full scope and M.E.A.C. Engineering could assert them against other defendants in the wound care space.
The public record does not disclose the parties’ negotiating positions. However, a 116-day resolution before claim construction is consistent with scenarios where either the defendant assesses credible infringement exposure, the parties have pre-existing commercial relationships, or both sides prefer confidential commercial terms over the cost and uncertainty of full litigation. Molnlycke’s engagement of a four-attorney team from Kilpatrick Townsend suggests the matter was taken seriously before settlement was reached.
Both patents are directed to wound closure and drainage system technology. This category broadly encompasses devices and methods used to close wounds and manage exudate or drainage, which may include systems related to negative-pressure wound therapy (NPWT), wound dressings with drainage channels, or integrated closure-drainage apparatus. The specific claim scope of each patent should be reviewed directly for FTO or design-around purposes.
PatSnap Eureka searches patents and litigation data to answer instantly.